These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33030799)

  • 1. Metabolic heterogeneity of human hepatocellular carcinoma: implications for personalized pharmacological treatment.
    Berndt N; Eckstein J; Heucke N; Wuensch T; Gajowski R; Stockmann M; Meierhofer D; Holzhütter HG
    FEBS J; 2021 Apr; 288(7):2332-2346. PubMed ID: 33030799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver cancer cell lines distinctly mimic the metabolic gene expression pattern of the corresponding human tumours.
    Nwosu ZC; Battello N; Rothley M; Piorońska W; Sitek B; Ebert MP; Hofmann U; Sleeman J; Wölfl S; Meyer C; Megger DA; Dooley S
    J Exp Clin Cancer Res; 2018 Sep; 37(1):211. PubMed ID: 30176945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic reprogramming enables hepatocarcinoma cells to efficiently adapt and survive to a nutrient-restricted microenvironment.
    Cassim S; Raymond VA; Dehbidi-Assadzadeh L; Lapierre P; Bilodeau M
    Cell Cycle; 2018; 17(7):903-916. PubMed ID: 29633904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Lipid and Lipid Droplet Metabolism in Human HCC.
    Berndt N; Eckstein J; Heucke N; Gajowski R; Stockmann M; Meierhofer D; Holzhütter HG
    Cells; 2019 May; 8(5):. PubMed ID: 31137921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.
    Ding X; He M; Chan AWH; Song QX; Sze SC; Chen H; Man MKH; Man K; Chan SL; Lai PBS; Wang X; Wong N
    Gastroenterology; 2019 Dec; 157(6):1630-1645.e6. PubMed ID: 31560893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. E3 ligase ZFP91 inhibits Hepatocellular Carcinoma Metabolism Reprogramming by regulating PKM splicing.
    Chen D; Wang Y; Lu R; Jiang X; Chen X; Meng N; Chen M; Xie S; Yan GR
    Theranostics; 2020; 10(19):8558-8572. PubMed ID: 32754263
    [No Abstract]   [Full Text] [Related]  

  • 7. MiR-3662 suppresses hepatocellular carcinoma growth through inhibition of HIF-1α-mediated Warburg effect.
    Chen Z; Zuo X; Zhang Y; Han G; Zhang L; Wu J; Wang X
    Cell Death Dis; 2018 May; 9(5):549. PubMed ID: 29748591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced glucose metabolism mediated by CD147 contributes to immunosuppression in hepatocellular carcinoma.
    Li X; Zhang Y; Ma W; Fu Q; Liu J; Yin G; Chen P; Dai D; Chen W; Qi L; Yu X; Xu W
    Cancer Immunol Immunother; 2020 Apr; 69(4):535-548. PubMed ID: 31965268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational Analysis of Transcriptomic and Proteomic Data for Deciphering Molecular Heterogeneity and Drug Responsiveness in Model Human Hepatocellular Carcinoma Cell Lines.
    Agioutantis PC; Loutrari H; Kolisis FN
    Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32517019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eukaryotic translation initiation factor 5A2 promotes metabolic reprogramming in hepatocellular carcinoma cells.
    Cao TT; Lin SH; Fu L; Tang Z; Che CM; Zhang LY; Ming XY; Liu TF; Tang XM; Tan BB; Xiang D; Li F; Chan OY; Xie D; Cai Z; Guan XY
    Carcinogenesis; 2017 Jan; 38(1):94-104. PubMed ID: 27879277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes.
    Bidkhori G; Benfeitas R; Klevstig M; Zhang C; Nielsen J; Uhlen M; Boren J; Mardinoglu A
    Proc Natl Acad Sci U S A; 2018 Dec; 115(50):E11874-E11883. PubMed ID: 30482855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cooperation Between Distinct Cancer Driver Genes Underlies Intertumor Heterogeneity in Hepatocellular Carcinoma.
    Molina-Sánchez P; Ruiz de Galarreta M; Yao MA; Lindblad KE; Bresnahan E; Bitterman E; Martin TC; Rubenstein T; Nie K; Golas J; Choudhary S; Bárcena-Varela M; Elmas A; Miguela V; Ding Y; Kan Z; Grinspan LT; Huang KL; Parsons RE; Shields DJ; Rollins RA; Lujambio A
    Gastroenterology; 2020 Dec; 159(6):2203-2220.e14. PubMed ID: 32814112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysregulated signaling hubs of liver lipid metabolism reveal hepatocellular carcinoma pathogenesis.
    Lee S; Mardinoglu A; Zhang C; Lee D; Nielsen J
    Nucleic Acids Res; 2016 Jul; 44(12):5529-39. PubMed ID: 27216817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated proteogenomic analysis revealed the metabolic heterogeneity in noncancerous liver tissues of patients with hepatocellular carcinoma.
    Liao H; Du J; Wang H; Lan T; Peng J; Wu Z; Yuan K; Zeng Y
    J Hematol Oncol; 2021 Dec; 14(1):205. PubMed ID: 34895304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell Culture System for Analysis of Genetic Heterogeneity Within Hepatocellular Carcinomas and Response to Pharmacologic Agents.
    Gao Q; Wang ZC; Duan M; Lin YH; Zhou XY; Worthley DL; Wang XY; Niu G; Xia Y; Deng M; Liu LZ; Shi JY; Yang LX; Zhang S; Ding ZB; Zhou J; Liang CM; Cao Y; Xiong L; Xi R; Shi YY; Fan J
    Gastroenterology; 2017 Jan; 152(1):232-242.e4. PubMed ID: 27639803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clear cell hepatocellular carcinoma: origin, metabolic traits and fate of glycogenotic clear and ground glass cells.
    Bannasch P; Ribback S; Su Q; Mayer D
    Hepatobiliary Pancreat Dis Int; 2017 Dec; 16(6):570-594. PubMed ID: 29291777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular carcinoma associated lipid metabolism reprogramming.
    Skill NJ; Scott RE; Wu J; Maluccio MA
    J Surg Res; 2011 Jul; 169(1):51-6. PubMed ID: 19932908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrative functional genomic analysis unveils the differing dysregulated metabolic processes across hepatocellular carcinoma stages.
    Ramesh V; Ganesan K
    Gene; 2016 Aug; 588(1):19-29. PubMed ID: 27107678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deregulated GATA6 modulates stem cell-like properties and metabolic phenotype in hepatocellular carcinoma.
    Tan HW; Leung CO; Chan KK; Ho DW; Leung MS; Wong CM; Ng IO; Lo RC
    Int J Cancer; 2019 Oct; 145(7):1860-1873. PubMed ID: 30834518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LINC01554-Mediated Glucose Metabolism Reprogramming Suppresses Tumorigenicity in Hepatocellular Carcinoma via Downregulating PKM2 Expression and Inhibiting Akt/mTOR Signaling Pathway.
    Zheng YL; Li L; Jia YX; Zhang BZ; Li JC; Zhu YH; Li MQ; He JZ; Zeng TT; Ban XJ; Yuan YF; Li Y; Guan XY
    Theranostics; 2019; 9(3):796-810. PubMed ID: 30809309
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.